Storylines

The big science stories, followed.

Some discoveries are not one day's news but a story that unfolds over months. Each storyline is one ongoing science arc, kept as a dated, sourced timeline the morning letter extends. Every promise made along the way is tracked until it is kept or broken.

Storylines: 54
Dated beats: 159
Promises tracked: 9
Still open: 7

See every promise in one place, kept and slipped

Psychology & Behavioral Science Active Psilocybin's move into the clinic Once taboo, psilocybin is being tested as a fast-acting treatment for depression and suicidal thoughts, with early and surprising signals in advanced dementia. Latest · Aug 2, 2026 A study using the 2024 National Survey Investigating Hallucinogenic Trends, led by Anita Cservenka of Oregon State University, found adults who used psilocybin alongside alcohol reported fewer depressive symptoms than adults who drank but did not use psilocybin, though the observational design cannot establish that psilocybin caused the difference. 8 beats 1 promise, 1 open The story so far Natural Sciences Active Two new 'ghost' ancestor lineages found in human DNA Researchers built a new method to reconstruct family trees across hundreds of modern human genomes and are finding traces of extinct archaic human populations that left no known fossils. The stakes are whether this genomic approach can recover parts of human population history, especially in Africa and the tropics, that fossil and ancient-DNA evidence has never been able to reach. Latest · Aug 2, 2026 ScienceDaily reported further detail from the same UC Berkeley team: the ghost lineage found in all modern humans contributed about 1% of the genome, similar to the Neanderthal share, and split from our ancestors around 800,000 years ago, while the super-archaic lineage traced back roughly 1.8 million years and interbred with Denisovans in Eurasia over 200,000 years ago before that Denisovan DNA reached modern humans. 2 beats The story so far Life Sciences & Medicine Active Lifestyle trials show measurable dementia prevention effects Large randomized trials are testing whether lifestyle interventions, exercise, brain training, social engagement, can lower the risk factors behind dementia, including the first such trial adapted for Latin America. The stakes are whether these gains hold up over years and translate into fewer actual dementia diagnoses, and whether the approach works outside the wealthy countries where most of this research has happened. Latest · Aug 2, 2026 Researchers reported at the Alzheimer's Association International Conference in London that LatAm-FINGERS, a trial of 1,200 adults aged 60 to 77 testing a culturally adapted lifestyle intervention pairing exercise with brain training against a control group given only general health advice, produced statistically better thinking skills in the intervention group, building on the Lancet Commission's 2024 estimate that 14 modifiable factors account for 45% of dementia cases worldwide. 1 beat The story so far Life Sciences & Medicine Active A cochlear implant for vision Science Corporation's retinal implant restores enough central vision for people who lost it to age-related macular degeneration to read books and recognize road signs again. The arc will run as the device, just cleared for commercial sale in Europe, moves toward a possible US launch and wider real-world use. Latest · Aug 1, 2026 SingularityHub reported that Science Corporation's PRIMA implant, a chip smaller than a grain of rice paired with camera-mounted glasses, produced an average gain of 25.5 letters, more than five lines, on a standard eye chart across a 38-patient trial in five countries, and the company said the first commercial implants are expected in Germany within weeks. 3 beats The story so far Natural Sciences Active A molecular brace targets the toxic clumps behind Parkinson's Alpha-synuclein, a protein long considered undruggable because it lacks the pocket-shaped binding sites conventional drugs need, is one of the primary drivers of neuron damage in Parkinson's disease. Researchers built a synthetic molecule called SK-129 that binds several parts of the protein at once and holds it in a shape resistant to clumping, and the stakes are whether this approach can move from mice toward a treatment that touches the underlying disease rather than just its symptoms. Latest · Aug 1, 2026 The Conversation reported that a synthetic molecule called SK-129, built to bind several parts of the protein alpha-synuclein and hold it in a shape resistant to clumping, blocked the clumping and spreading of the protein and reduced disease symptoms in mice, particularly when it targeted the earliest, most dangerous clumps before they grew. 1 beat The story so far Life Sciences & Medicine Active Preventing long COVID before it starts Two separate randomized trials found that drugs already sitting in medicine cabinets, the antiviral Paxlovid and the diabetes drug metformin, can cut the risk of developing long COVID when given during an acute infection. The stakes are whether prevention during the initial infection can sidestep a condition that has proven very hard to treat once it sets in, especially since metformin costs pennies a pill and is already prescribed to millions. Latest · Aug 1, 2026 Nature reported that Paxlovid cut the risk of developing long COVID within three months by 40 percent when given during acute COVID-19 infection, and metformin cut the six-month risk by around half, though physicians remain split on whether the trial results are strong enough to justify prescribing either drug for this purpose now. 1 beat The story so far Plant-Based & Vegan Active Public opinion and factory farming keep drifting apart, then back together Surveys keep finding that most people oppose common factory-farming practices, yet the vast majority of farmed animals are raised on factory farms and meat consumption keeps rising. The arc tracks whether policy and corporate commitments, like cage-free pledges and national farming roadmaps, start closing that gap. Latest · Aug 1, 2026 Sentient reported that Iowa's confined animal feeding operations grew 13 percent over six years even as Iowa voters oppose weakening the state's animal welfare laws by nearly two to one in a new poll, while the state now slaughters more than 39 million hogs a year. 9 beats The story so far Technology & Innovation Active The clean-energy tipping point Solar power and storage are crossing milestones that reorder the grid, even against policy headwinds. Latest · Aug 1, 2026 Good News Network reported that 46 percent of new US homes built last year came with a heat pump already installed, with heat pump sales now outpacing older gas furnace systems by 32 percent. 8 beats 1 promise, 1 open The story so far Life Sciences & Medicine Active The many-fronted fight against Alzheimer's Researchers are attacking Alzheimer's from several directions at once: the biology of how it spreads, drugs that reprogram the brain's immune cells, and blood tests that could catch it years early. Latest · Aug 1, 2026 New Scientist reported that thousands of people in China have received a lymphatic drainage surgery for Alzheimer's that remains banned in most countries, after small safety trials in the US and Singapore found it safe for up to six months with some signs of cognitive improvement, and a randomized trial against a sham procedure is now underway to test whether it actually works. 13 beats 1 promise, 1 open The story so far Plant-Based & Vegan Active Livestock farmers convert to plant-based agriculture The Transfarmation Project helps farmers who raised pigs, chickens or other livestock convert their operations to plant-based agriculture, then opens the converted farms as demonstration hubs other producers can visit. The arc will run as more farmers, including in major animal-agriculture states, complete similar transitions and as the hub network grows. Latest · Jul 31, 2026 Iowa's Faaborg family converted three decades of hog farming into a specialty mushroom operation called 1100 Farm, which opened as the Transfarmation Project's second demonstration hub, betting on a North American specialty mushroom market projected to reach $5.58 billion by 2030. 1 beat The story so far Life Sciences & Medicine Active Closing the organ shortage from two directions More than 104,000 Americans are waiting for a kidney and 17 die every day before one arrives. Two separate advances, a supercooling technique that keeps kidneys viable for days instead of hours and a shift toward donation after circulatory death rather than only brain death, are each expanding the organ supply, and the arc will run as both move from early results toward wider clinical use. Latest · Jul 30, 2026 Reasons to be Cheerful reported that voucher-based kidney donation chains let a donor give locally while pushing a friend's intended recipient to the top of their own region's waitlist, producing better regional matches than a direct swap could. Only about 500 Americans donate a kidney to a stranger each year even though more than 90,000 people are on the US kidney waitlist and 12 to 17 die waiting daily. 2 beats The story so far Natural Sciences Active The gut sends a real-time memory signal to the brain Researchers are finding that the gut sends signals through the vagus nerve that shape which experiences the brain converts into memory, not just hunger or fullness. The stakes are whether this gut-to-brain memory pathway operates in humans and could explain why some meals and experiences stick in memory while others do not. Latest · Jul 30, 2026 Scott Kanoski's lab at USC found that a nutrient-rich meal triggered a surge of acetylcholine, a neurotransmitter that helps the brain record new information, in neurons wired to the hippocampus in rats, and that surge vanished when researchers cut the vagus nerve running from gut to brain. Sugar water that tasted just as sweet but carried no real nutrition produced no such surge, and rats with a cut vagus nerve also got worse at remembering where they had just found food. 1 beat The story so far Natural Sciences Active Making geothermal power work anywhere Geothermal power has long depended on a geographic accident, fault lines bringing hot rock close to the surface, that makes it work well in Iceland and barely anywhere else. Companies including Quaise Energy are developing drilling deep enough into hot rock to remove that dependence, aiming to give any country access to steady, round-the-clock clean power. The open stakes are whether the drilling can be done affordably at industrial scale. Latest · Jul 30, 2026 Zanskar revived Lightning Dock, a cooling geothermal plant in New Mexico, by drilling a new well to 8,000 feet after finding the original wells, at 2,500 feet, barely reached the edge of the underground reservoir. The deeper well came online in May 2025 and a year later was still pumping more than 4,000 gallons of hot water a minute, reversing a plant that had been losing 50 degrees Fahrenheit of water temperature over five years, five times the normal rate of decline. 2 beats The story so far Psychology & Behavioral Science Active A single dose of LSD sharpens motor skill learning in healthy adults A randomized, placebo-controlled trial gave healthy adults a single dose of LSD and found it improved learning and retention of a typing task for up to a week afterward, alongside changes in BDNF, a hormone tied to brain plasticity. The stakes are whether a psychedelic can open a real window of heightened plasticity useful for skill learning, not just mood. Latest · Jul 29, 2026 A University of Fribourg team running the LSD motor-learning trial as a randomized, double-blind crossover study in 45 volunteers aged 21 to 55 reported lower perceived stress lasting up to a week after dosing, plus lingering shifts in how the brain processes sound and muscle-control signals. 2 beats The story so far Natural Sciences Active Protacs: drugs that destroy their target instead of blocking it Protacs, a drug class first proposed in 2001, grab a disease-causing protein and drag it to the cell's own disposal system rather than just binding and blocking it, letting them act on proteins long considered undruggable. The first protac drug won approval this year, two decades after the idea began as a lab curiosity, and the arc will run as more protacs move toward patients. Latest · Jul 29, 2026 New Scientist reported the approval this year of the first protac drug, a class that destroys disease-causing proteins by tagging them for the cell's disposal system instead of simply blocking them, opening treatment options for proteins previously considered undruggable. 1 beat The story so far Natural Sciences Active A hands-off way to entangle qubits over distance Physicists at the Institute of Science and Technology Austria and the Technical University of Munich entangled qubits automatically by exposing them to a shared bath of low-energy microwaves, replacing finicky single-photon methods. The stakes are whether this low-maintenance entanglement can scale to the arbitrary distances needed for real quantum computers. Latest · Jul 29, 2026 A team at the Institute of Science and Technology Austria and the Technical University of Munich confirmed a 20-year-old theory by entangling two distant qubits automatically using a shared low-energy microwave bath, with no active photon-matching required, testing it across about 20 inches of cable. 1 beat The story so far Natural Sciences Active The body's hidden light detectors For decades opsins were assumed to exist only so the eye can see, but researchers keep finding melanopsin, encephalopsin and neuropsin in skin, blood vessels and immune cells, where they appear to track daylight rather than form images. The stakes are whether this non-visual light sensing turns out to shape human mood, circadian rhythm, metabolism and fat storage, and whether doctors start factoring light exposure into treatment as a result. Latest · Jul 28, 2026 Knowable Magazine reported that opsins, the light-sensitive proteins long thought to exist only for vision, also turn up in human skin, blood vessels and immune cells, with the strongest evidence so far linking them to mood regulation and the body's daily rhythms and early studies hinting at roles in fat storage, metabolism and eye development. 1 beat The story so far Life Sciences & Medicine Active Blood biomarkers now predict when ALS symptoms begin The NIH-funded Pre-fALS study has tracked people carrying ALS-linked genes for nearly 20 years, and researchers have now turned that data into a blood test that estimates how close someone is to developing symptoms. The stakes are enrolling genetically at-risk people in preventive trials before irreversible motor neuron damage starts, and whether the same approach can eventually help predict onset in ALS cases without a known inherited variant. Latest · Jul 28, 2026 A Pre-fALS study team led by Michael Benatar of the University of Miami analyzed blood plasma from 137 people carrying ALS-associated genes, measured more than 5,000 proteins, and identified a panel of 19 proteins, including neurofilament light chain, that together estimate when someone will become symptomatic to within about 18 months on average. 1 beat The story so far Natural Sciences Active SuperAgers keep sharp memory into their 90s, and it isn't genetic Researchers at the University of Chicago's HAARC Center and TGen compared the genomes of SuperAgers, people who reach their 80s and 90s with memory as sharp as someone decades younger, to cognitively average older adults and found no genetic difference. The stakes are finding what, if not genetics, protects some older adults' memory so the protection might eventually be studied and shared rather than left to chance. Latest · Jul 27, 2026 A study of 125 adults aged 71 to 101 in Sardinia's Blue Zone found the region's long-lived residents scored higher on openness, had better coping strategies, and engaged in more frequent hobbies than people living just outside the zone. 2 beats The story so far Social Sciences Active South America's hunger rate falls to a record low A UN Food and Agriculture Organisation report found hunger in South America fell by a third since 2020 to 3.5 percent of the population, the fastest decline of any region and the lowest level ever recorded there. The stakes are whether the region can reach the FAO's stated potential of zero hunger by 2030, and whether countries like Suriname that are still moving the wrong direction get pulled along. Latest · Jul 27, 2026 A UN FAO report released July 21 found South American hunger fell by a third since 2020 to 3.5 percent, the lowest ever recorded in the region, with Brazil, Chile and Guyana removed from the UN's Hunger Map and Argentina, Colombia, Paraguay, Peru and Venezuela all near or under 5 percent. FAO chief economist Maximo Torero said South America could potentially reach zero hunger by 2030, while Suriname remained an exception still heading the wrong direction. 1 beat The story so far Solutions & Good News Active Europe's first sanctuary for working elephants opens in Portugal Julie, Portugal's last circus elephant, moved into Pangea Elephant Sanctuary, a new 1,000-acre reserve in Alentejo built after Portugal banned wild animal circus performances. The stakes are whether the sanctuary can build out barns and fencing fast enough to take in more elephants, including a second elephant, Kariba, expected to join later this year. Latest · Jul 27, 2026 Julie, captured as a calf in Africa in the late 1980s and performing in Portuguese circuses since 1988, moved on June 30 into Pangea Elephant Sanctuary's 1,000-acre home in Alentejo, becoming its first resident. Managing director Kate Moore said the sanctuary hopes to eventually house 20 to 35 elephants, with a second elephant, Kariba, currently alone at a Belgian zoo, expected to join later this year. 1 beat The story so far Life Sciences & Medicine Active A monthly HIV prevention pill gets licensed before it's even approved Merck's experimental once-monthly HIV prevention pill alimatravir is still in two late-stage clinical trials, but the company has already signed royalty-free voluntary licensing deals with seven generic manufacturers to supply 129 low- and middle-income countries the moment it wins approval. The arc will run as the trials conclude and as this early-licensing model is tested against the years-long delays that slowed past HIV drugs from reaching the countries carrying the heaviest burden. Latest · Jul 25, 2026 Merck signed voluntary, royalty-free licensing deals with seven generic manufacturers, three in Africa and four in India, to make and sell its experimental HIV prevention pill alimatravir across 129 low- and middle-income countries as soon as it clears its still-ongoing late-stage clinical trials. 1 beat The story so far Technology & Innovation Active AI starts designing CRISPR gene editors from scratch Researchers are using AlphaFold-style AI models to redesign CRISPR nucleases for higher precision and to design entirely new gene-editing proteins with no natural counterpart. The stakes are whether AI-generated editors can cut the off-target and bystander editing that has kept CRISPR from being safe enough for a wider range of diseases. Latest · Jul 25, 2026 Researchers used AlphaFold-style AI to redesign existing CRISPR nucleases for higher fidelity than earlier hand-tuned versions, and in a separate study used AI to design entirely new gene-editing proteins from scratch that successfully edited genes in cells from multiple species despite having no natural counterpart. 1 beat The story so far Plant-Based & Vegan Active Growing dairy proteins without the cow Startups are using molecular farming and precision fermentation to produce real dairy proteins, casein and lactoferrin, without any animal involved, aiming to match the taste, function and price of conventional dairy. The arc will run as these products move from lab claims to commercial kitchens and store shelves at scale. Latest · Jul 23, 2026 Israeli startup Plantopia raised $9 million, led by dairy giant Schreiber Foods, to grow casein inside sprouted oats on vertical farms. The company says it has matched all four forms of cow casein and their coagulation behavior at $15 to $20 per kilogram, on par with conventional dairy, with production starting this quarter at a facility in Kibbutz Sdot Yam. 1 beat The story so far Technology & Innovation Active Brain implants leave the lab Brain-computer interfaces are moving from lab demos that needed a technician to devices people use unaided at home, restoring speech and movement to people with paralysis. Latest · Jul 23, 2026 Feinstein Institutes researchers reported in Nature that Keith Thomas's double neural bypass, in which electrodes read his intention to move and route it past his spinal injury to his arms while sensors send touch signals back, raised his right arm strength 86 percent and his left arm 62 percent after 35 weeks of training. He can now scratch his nose, wipe his mouth and pet his dog, and some function has persisted even with the system switched off. 6 beats 1 promise, 1 open The story so far Solutions & Good News Active Bringing back the American chestnut A fungal blight introduced from East Asia in the early 1900s wiped out billions of American chestnut trees. Researchers and startups are now using a blight-tolerance gene, genomic prediction and speed-breeding to restore the species, with hopes of applying the same approach to other pest-hit hardwoods like elm, ash and oak. Latest · Jul 23, 2026 The Conversation reported that OXO, a single inserted wheat gene that for about 20 years looked like it might make American chestnuts fully blight-resistant on its own, is underperforming in recent field results, prompting researchers to design new genetic strategies informed by the tree's full genome rather than betting on one gene. 2 beats The story so far Life Sciences & Medicine Active A one-hour brush test for oral cancer Standard oral cancer biopsies are painful enough in a sensitive area that patients needing repeat monitoring often stop showing up, letting dangerous lesions go undetected. Queen Mary University of London researchers built qMIDS, a brush swab reading mRNA activity from four genes, as a painless alternative delivering results in under an hour. The arc will run as the test moves toward commercialization and regulatory approval. Latest · Jul 22, 2026 Researchers at Queen Mary University of London, working with partners in India, tested a brush swab called qMIDS on 545 patients with suspicious mouth lesions and found 95.5 percent overall accuracy, with false-positive and false-negative rates each under 5 percent, comparable to a microbiopsy. Oral oncologist Muy-Teck Teh said he expects the test could reach clinics within two years. 1 beat The story so far Natural Sciences Active Classical computers keep matching quantum advantage claims Physicists periodically claim a quantum computer has solved a problem beyond any classical machine's reach, and other researchers keep testing those claims against improved classical methods like tensor networks. The arc tracks whether classical hardware keeps closing the gap or whether some future claim finally holds. Latest · Jul 21, 2026 Joseph Tindall and Miles Stoudenmire of the Simons Foundation's Flatiron Institute used tensor networks, a technique for compressing complex quantum wave functions, to reproduce on classical hardware, including a personal laptop, results a team had claimed required a quantum computer to model hundreds of entangled qubits, matching both the theoretical predictions and the quantum computer's own output. 1 beat The story so far Technology & Innovation Active India's commercial space sector reaches orbit Skyroot Aerospace, a private Indian rocket company, put its Vikram-1 launcher into orbit on its first attempt, becoming India's first fully commercial satellite launcher. The arc will run as Skyroot tries to turn one successful debut into a reliable, frequent launch business the way SpaceX and Rocket Lab eventually did. Latest · Jul 20, 2026 Skyroot Aerospace's Vikram-1, a 72-foot rocket capable of carrying payloads up to 770 pounds, launched from Sriharikota and reached an orbit about 280 miles high on its first attempt, becoming India's first fully commercial satellite launcher built by a private company rather than the national space agency. 1 beat The story so far Life Sciences & Medicine Active A treatment finally emerges for long COVID fatigue Long COVID fatigue has been one of medicine's most disabling and least understood complaints, with no proven treatment despite sidelining millions of people from work and family life. A randomized trial testing existing, inexpensive drugs against placebo has begun to identify what actually helps and by how much. Latest · Jul 19, 2026 In a placebo-controlled trial of 399 adults in Brazil who had unrelenting post-COVID fatigue for at least 90 days, researchers led by Edward Mills of McMaster University found fluvoxamine, a cheap antidepressant on the market since the 1990s, had a 99 percent probability of beating placebo on fatigue, while metformin was also tested in the same trial. 1 beat The story so far Social Sciences Active Congress passes its biggest housing law in 30 years The 21st Century ROAD to Housing Act, signed into law July 11, is the first major federal housing legislation in about 30 years and is built on the idea that scarce housing quietly drives inequality, slow growth and even falling fertility. The arc will run as implementation unfolds town by town against local zoning boards that have long controlled the issue. Latest · Jul 19, 2026 The 21st Century ROAD to Housing Act became law on July 11 after passing the Senate 85-5 and the House 358-32, the first major federal housing legislation in about 30 years. One estimate holds that building restrictions in New York, San Francisco and San Jose alone cost the US economy $8,775 per worker a year, while a record 22.6 million renter households, half of all renters, spend more than 30 percent of their income on housing. 1 beat The story so far Technology & Innovation Active A satellite network built to catch wildfires while they're still small Google and the Bezos Earth Fund backed FireSat, a constellation of satellites designed to spot wildfires as small as 16 by 16 feet through smoke and cloud cover. The arc will run as the fleet grows from three satellites to more than 50 over the next decade, scaling from twice-daily to 20-minute global checks. Latest · Jul 18, 2026 The first three satellites in the Google-backed FireSat constellation launched July 7 from Vandenberg Space Force Base, carrying multispectral imaging able to spot fires as small as 16 by 16 feet. Google contributed 15 million dollars and the Bezos Earth Fund 26 million dollars; fire agencies in California, Colorado, Australia and Portugal begin using the data this year, with the network scaling toward hourly global checks by 2029 and 20-minute checks once more than 50 satellites are in orbit in the early 2030s. 1 beat The story so far Natural Sciences Active Apophis's once-in-a-generation flyby In April 2029, the asteroid Apophis will pass closer to Earth than many satellites, becoming visible without a telescope to about 90 percent of the world's population. Scientists plan to keep tracking it closely before, during and after the flyby to see whether Earth's gravity nudges its future path. Latest · Jul 18, 2026 Scientists at the Apophis T-3 Years workshop in Padua, Italy, mapped who will be able to see asteroid Apophis when it passes within roughly 19,000 miles of Earth on April 13, 2029, finding up to 7.6 billion people, about 90 percent of the world's population, will be able to see it with the naked eye. Researchers say there is currently zero chance of impact this pass or within the next century. 1 beat The story so far Natural Sciences Active The first atmosphere found on a small, temperate rocky world Astronomers spent decades hunting for an atmosphere around a small, rocky planet sitting in its star's habitable zone without success, wondering if small stars simply strip these worlds bare. LHS 1140b, 50 light years away, just became the first exception, and unpublished James Webb Space Telescope data could soon reveal whether it holds an ocean or is closer to a scaled-down gas giant. Latest · Jul 17, 2026 Collin Cherubim of Harvard and colleagues used the Las Campanas Observatory in Chile to detect excited-state helium leaking from LHS 1140b, a rocky planet in its small star's habitable zone, the first confirmed atmosphere on a small temperate rocky world. Cherubim said the planet has now become the best place to search for life outside our solar system. 1 beat The story so far Life Sciences & Medicine Active Reversing aging by fixing the body's cellular cleanup crew Stanford researchers found that aging jams the receptor macrophages use to clear out spent neutrophils, letting toxic cells pile up and leak inflammation into organs throughout the body. Blocking that single receptor reversed signs of aging across the liver, muscle, fat and brain in mice, and the same broken pattern turned up in aging human liver tissue. Latest · Jul 17, 2026 Stanford researchers found that the hormone prostaglandin E2 jams macrophages' ability to clear spent neutrophils through a receptor called EP2, and blocking EP2 in aged mice restored 59 of 71 previously abnormal blood proteins to youthful levels, along with leaner body composition, better grip strength and sharper memory. The team found the same pattern of stuck neutrophils and inflammation in older, diseased human liver tissue. 1 beat The story so far Life Sciences & Medicine Active GLP-1 drugs, beyond weight loss The GLP-1 drugs are turning out to change mood, behavior and the brain's relationship with food, not just body weight, as coverage expands to older adults. Latest · Jul 17, 2026 A new study found GLP-1 receptor agonists reduced symptoms of binge eating, adding another behavioral effect to the drugs' expanding profile beyond weight loss. 7 beats 1 promise, 1 open The story so far Natural Sciences Active A tabletop black hole recreates Hawking's radiation Physicists led by Ulf Leonhardt at the Weizmann Institute built a black hole analogue inside a strand of optical fiber using a fast-moving light pulse, and detected Hawking radiation, the faint thermal glow theory predicts should leak from a black hole's edge, along with the elusive back-reaction of that glow feeding energy into the object producing it. The arc will run as researchers test whether the same physics scales toward anything closer to a real black hole or stays a lab-only effect. Latest · Jul 16, 2026 A team led by Ulf Leonhardt at the Weizmann Institute of Science built a black hole analogue in optical fiber and, publishing in Nature on July 1, detected both Hawking radiation and its back-reaction on the analogue for the first time, with the light showing a real temperature and a spectrum that held up even where standard black hole equations should have broken down. 1 beat The story so far Life Sciences & Medicine Active Cracking a 15-year mystery in how a gut toxin causes colon cancer A toxin called BFT, made by a gut bacterium carried by up to 20 percent of healthy people, has been linked to colorectal cancer for over 15 years without anyone knowing how it entered colon cells. A Johns Hopkins team led by Cynthia Sears found the receptor it binds, claudin-4, and built a decoy protein that blocked the toxin in mice. The arc will run as that decoy moves toward testing in people. Latest · Jul 16, 2026 A Johns Hopkins team led by Cynthia Sears, working with Harvard Medical School, ran a genome-wide CRISPR screen and identified claudin-4 as the receptor the gut toxin BFT must bind to enter colon cells, then built a decoy protein that intercepted the toxin and protected mice from damage to the colon's protective barrier. 1 beat The story so far Technology & Innovation Active A vaccine push to save Australia's koalas from chlamydia Roughly half of Australia's remaining koalas carry chlamydia, which causes blindness and infertility and is splintering already-isolated populations toward local extinction. Queensland researchers are testing whether a single-visit vaccine, combining an injection with a slow-release implant, can protect wild koalas without the difficulty of recapturing them for a second dose. Latest · Jul 14, 2026 An 18-month-old koala named Bamse, captured near Burleigh, Queensland, became the first koala vaccinated against chlamydia with a new combination shot developed with Queensland University of Technology, one injection plus an implant that releases a second dose on its own over 30 days. Bamse now wears a GPS collar so vets at Currumbin Wildlife Hospital can monitor her over the next six months. 1 beat The story so far Natural Sciences Active Sugars and life's building blocks keep turning up in space Astronomers keep finding molecules central to biology, sugars and other prebiotic chemistry, already present in interstellar gas clouds and comets, long before any planet exists to use them. The arc tracks whether this chemistry is common throughout the galaxy and how much of it could survive the trip to a planet's surface intact. Latest · Jul 14, 2026 Astronomers using Spain's Yebes 40-meter and IRAM 30-meter radio telescopes detected erythrulose, a four-carbon sugar also found in raspberries, in a gas and dust cloud called G+0.693-0.027 near the Milky Way's center, the first time this sugar has been found outside the solar system. Erythrulose can convert into threose, a sugar some researchers think was a building block of the first nucleic acids that became RNA and DNA. 1 beat The story so far Life Sciences & Medicine Active A shot that reverses osteoarthritis University of Colorado Boulder researchers built two therapies in two years: an injectable that delivers an FDA-approved drug into a joint in sustained bursts, and a biomaterial repair kit that recruits the body's own cells to patch cartilage and bone defects. In animals the injection returned arthritic joints to a healthy state within four to eight weeks, and the patches produced what the team called full regeneration. The arc will run as these move from animal and human-cell testing toward people, aiming to fill the current gap between pain management and joint replacement. Latest · Jul 13, 2026 A University of Colorado Boulder team led by Stephanie Bryant reported a regenerative injection that returned arthritic joints in animals to a healthy state within four to eight weeks, and a separate biomaterial repair kit, injected arthroscopically, that produced what Bryant called full regeneration and repair when used to patch cartilage or bone defects. 1 beat The story so far Natural Sciences Active Black holes built from earlier black hole mergers Eleven years after LIGO's first detection of two black holes merging, the gravitational-wave catalog has grown to 390 confirmed events, some too heavy for a single dying star to have produced on its own. The leading explanation is that these are second-generation black holes, formed when black holes that already merged once merge again. The arc will run as astronomers try to work out how common these repeat mergers are and where the first-generation black holes that produce them come from. Latest · Jul 13, 2026 As of June 2026, LIGO's gravitational-wave catalog stood at 390 confirmed detections since its first-ever direct detection in 2015 of two black holes of about 36 and 29 solar masses merging. Some of the newly found black holes are heavier than a single collapsing star should produce, leading astronomers to conclude they are second-generation objects built from an earlier black hole merger. 1 beat The story so far Natural Sciences Active A gut bacterium that hunts tumors Researchers at the Japan Advanced Institute of Science and Technology isolated dozens of bacterial strains from the intestines of frogs, newts and lizards and found one that eliminates tumors from the inside by multiplying in the oxygen-starved core of a tumor while recruiting the immune system's own cells. The arc will run as the approach, tested only in mice so far, moves toward safety and efficacy testing beyond a single animal model. Latest · Jul 13, 2026 The Japan Advanced Institute of Science and Technology team said Ewingella americana came from screening 45 bacterial strains taken from the intestines of tree frogs, fire belly newts and grass lizards, and reported the bacterium was undetectable in the bloodstream at 24 hours, showed zero colonization in healthy organs, and caused no chronic toxicity over 60 days of observation. The team plans to test it next against breast cancer, pancreatic cancer and melanoma. 5 beats The story so far Natural Sciences Active A new island rises from the Pacific Satellites are tracking a volcanic eruption building near Papua New Guinea's Bismarck Sea, the first time this kind of undersea eruption has been documented from the initial earthquake swarm through ash plumes and a mapped thermal hotspot. The arc will run as the vent either breaches the ocean surface into new land or subsides, in one of the least-mapped patches of ocean on the planet. Latest · Jul 12, 2026 On May 8, an earthquake swarm along Titan Ridge in the Bismarck Sea north of Papua New Guinea signaled a new eruption, and within days NASA's Aqua, Terra and PACE satellites and Europe's Sentinel-2 and Landsat 9 caught steam plumes, discolored water and ash reaching kilometers into the sky. By May 12, the VIIRS instrument had mapped an underwater thermal hotspot covering about seven square kilometers, though scientists still do not know how deep the vent sits or whether it will break the surface. 1 beat The story so far Psychology & Behavioral Science Active Depression splits into biologically distinct subtypes Large genetic studies and brain imaging are finding that major depression is not one disease but at least two, defined by opposite symptom patterns, while scans show the brain tissue changes chronic depression leaves behind can reverse with treatment. The arc will run as researchers try to turn subtype and imaging findings into tests that guide which patients get which drug. Latest · Jul 12, 2026 A genetics team analyzed three genome-wide association meta-analyses across more than 460,000 people and found major depression splits into two biological subtypes, AERS+ marked by hypersomnia and weight gain and AERS- marked by insomnia and weight loss, tied to 27 gene variants including several never reported before. Separately, brain scans of nearly 120 people with persistent depressive disorder treated with duloxetine or desvenlafaxine showed tissue changes from chronic depression normalizing with treatment, tracking with how much symptoms improved. 1 beat The story so far Technology & Innovation Active CAR T cell therapy takes aim at solid tumors CAR T cell therapy has worked wonders against blood cancers but has struggled against solid tumors like brain, breast and lung cancer because they share no single consistent target. Two independent research teams have now converged on the same cell-surface protein, GPNMB, which sits on both the cancer cells and the immune cells that shield tumors from attack. The arc will run as early single-patient and animal results are tested for durability and safety in larger trials. Latest · Jul 11, 2026 Sheila Singh's team at McMaster engineered CAR T cells against GPNMB that rapidly destroyed glioblastoma in patient tissue samples and shrank tumors in mice, while a second team used the same target against an aggressive soft-tissue cancer, and one infusion in an early trial stabilized a single patient's disease for three months with no serious side effects. 5 beats The story so far Natural Sciences Active Black holes too massive for the young universe Telescopes keep finding supermassive black holes and quasars from within the universe's first billion years that are already billions of times the mass of the sun, far more massive than current models of black hole growth can explain. The arc is the accumulating fossil record from the early universe running ahead of any accepted mechanism for how these objects got so big so fast. Latest · Jul 10, 2026 The Euclid telescope found 31 of the oldest quasars ever detected, including the two earliest known, shining from a universe only about 670 million years old, each powered by a black hole billions of times the sun's mass. Co-author Joseph Hennawi of UC Santa Barbara and Leiden University said astronomers do not yet understand how they grew so massive so fast. 5 beats The story so far Psychology & Behavioral Science Active Metabolic interventions for mental illness A randomized controlled trial from UCSF found a ketogenic diet reduced clinical symptoms of schizophrenia and bipolar disorder and improved daily cognitive performance, with effects that held after controlling for weight loss. The working hypothesis is that antipsychotic medications often disrupt the brain's ability to use glucose, and ketones produced when the body runs on fat may restore fuel to neural circuits standard drugs cannot reach. The arc spans nutrition science, metabolic biology, and psychiatry, and will run as larger trials test whether the mechanism holds and whether dietary interventions can work outside a research setting. Latest · Jul 9, 2026 A UCSF randomized controlled trial published in Schizophrenia Bulletin found 83 percent of patients with schizophrenia or bipolar disorder maintained ketosis through a one-month primary phase, rising to 94 percent in a voluntary four-month extension, with no severe side effects reported. Psychiatric improvements held after researchers controlled for weight loss, and higher blood ketone levels correlated directly with sharper drops in both blood glucose and clinical depression scores, suggesting the effect is metabolic rather than a byproduct of slimming. 6 beats 1 promise, 1 open The story so far Technology & Innovation Active Humanoid robots enter the operating room A UCSD team conducted the first surgeries using teleoperated humanoid robots, completing a gallbladder removal with a surgeon assisting a single robot and a second procedure with two robots working together, both on large nonprimate animals. Unlike conventional robotic surgical systems that weigh hundreds of kilograms and require purpose-built rooms, the Surgie robots stand five feet tall and weigh 27 kilograms. The arc will run as the field works toward human trials, with force sensing in soft tissue, precision, and clinical safety identified as unsolved problems in the Nature study. Latest · Jul 9, 2026 A UCSD team completed the first surgeries using teleoperated humanoid robots, including a gallbladder removal with a surgeon assisting a single robot and a second procedure with two robots working together on large nonprimate animals. The peer-reviewed study in Nature evaluated the platform across benchtop characterization, dry-lab user studies, and live porcine trials, and was explicit that precision, force sensing in soft tissue, and clinical safety are challenges that remain unsolved before any move toward human patients. 6 beats The story so far Technology & Innovation Active A vaccine built for coronaviruses we have not met yet Researchers are trying to build one vaccine against the whole sarbecovirus family, the group that includes SARS, COVID-19 and the bat coronaviruses that have not yet jumped to humans, by aiming at the parts of the virus evolution has left largely untouched. The approaches include mosaic nanoparticles and AI-designed, fridge-stable DNA vaccines. Latest · Jul 8, 2026 Researchers at the University of Cambridge used AI to scan genetic data from thousands of sarbecoviruses, identify conserved targets a virus is unlikely to mutate without losing fitness, and design a DNA vaccine stable without refrigeration and delivered via needle-free high-pressure liquid injection. The vaccine entered human trials for the first time, aiming to protect against the entire sarbecovirus family including strains that do not yet exist. 6 beats 2 promises, 1 open The story so far Life Sciences & Medicine Active The brain cells that keep memories alive Astrocytes, star-shaped cells that make up roughly half the brain by cell count, were long dismissed as passive structural scaffolding for neurons. New research shows they are active gatekeepers deciding which long-term memories survive, with direct implications for Alzheimer's disease, autism spectrum disorder, and age-related memory loss. Latest · Jul 8, 2026 Researchers at the Institute of Basic Science found that astrocytes control long-term memory persistence through a protein called ankyrin-2 (Ank2). Mice engineered without Ank2 in their astrocytes formed memories completely normally but lost all long-term recall within two weeks while short-term memory stayed intact. The team also built a light-activated genetic tool called Opto-T1 that restores astrocyte function in living mice and successfully boosted long-term memory persistence. 7 beats The story so far Natural Sciences Active Building a living cell from parts Scientists are assembling the minimum machinery of life from scratch, testing whether the core functions of a living cell need anything mysterious at all. Latest · Jul 2, 2026 A synthetic cell nicknamed SpudCell was reported growing, copying its DNA and dividing, with about 30 percent still carrying DNA after five generations. 8 beats 1 promise The story so far Life Sciences & Medicine Active Switching mammal regeneration back on Mammals scar instead of regrow, but researchers are finding the regenerative machinery is silenced rather than lost, and can sometimes be switched back on. Latest · Jun 27, 2026 Epigenetic editing that switches genes on and off without changing the DNA sequence entered human trials for muscular dystrophy. 7 beats The story so far Natural Sciences Active Our ancient relatives, still in our genes Ancient human relatives like the Denisovans and Neanderthals are turning out to still shape modern immune systems, sometimes raising disease risk and sometimes protecting against it, and the gaps in our genetic databases matter for health. Latest · Jun 19, 2026 Researchers catalogued more than 3,000 Denisovan genetic variants active in modern immune cells, with some Papua New Guinean populations carrying up to about 5 percent Denisovan DNA. 7 beats The story so far

Every beat was reported in our daily letter on its date and links onward to the primary study. Every promise is tracked until it is kept or broken, never quietly dropped.